Ryzneuta
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Efbemalenograstim alfa
- Made by
- Fisiopharma S.r.l.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | Fisiopharma S.r.l. |
|---|---|
| Active substance | Efbemalenograstim alfa |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03AA18 · Cancer treatments and immune-system medicines |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2024-03-21 |
| Last updated by the regulator | 2026-08-19 |
| EMA product number | EMEA/H/C/005828 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).